Pharmacokinetic evaluation of losartan.

Détails

ID Serval
serval:BIB_C55118C53D15
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Pharmacokinetic evaluation of losartan.
Périodique
Expert Opinion on Drug Metabolism and Toxicology
Auteur(s)
Burnier M., Wuerzner G.
ISSN
1744-7607 (Electronic)
ISSN-L
1742-5255
Statut éditorial
Publié
Date de publication
2011
Volume
7
Numéro
5
Pages
643-649
Langue
anglais
Résumé
Introduction: Blockade of the renin-angiotensin system is one of the major therapeutic strategies in the management of patients with essential hypertension, congestive heart failure and diabetic as well as non-diabetic renal diseases. As the first angiotensin II receptor blocker (ARB) on the market, losartan belongs to the most frequently prescribed ARB. Area covered : The present review examines the pharmacokinetics of losartan with a special discussion on the dose of losartan that should be used in clinical practice to obtain the maximal benefits of the drug. Readers are provided with arguments suggesting that the dose of 50 mg losartan is probably too low and that losartan should preferably be prescribed at the dose of 100 mg/day or higher. Expert opinion : Losartan is an effective antagonist of angiotensin II AT(1) receptors which has been shown to provide important clinical benefits in patients with hypertension, congestive heart failure and renal diseases. Losartan should be prescribed at the dose of 100 mg/day and the use of higher doses should be reconsidered in future studies to improve its clinical efficacy.
Pubmed
Web of science
Création de la notice
13/05/2011 10:26
Dernière modification de la notice
03/03/2018 21:15
Données d'usage